by Kyle | Jan 17, 2023 | Press Release
Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
by Kyle | Jan 9, 2023 | Press Release
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...
by Kyle | Dec 13, 2022 | Press Release
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provision patent application...
by Kyle | Dec 6, 2022 | Press Release
SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today announced that its ophthalmic diagnostic tear based...
by Kyle | Oct 4, 2022 | Press Release
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initial order of 19,000...
by Kyle | Sep 29, 2022 | Press Release
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,”...